P. aeruginosa bloodstream infections among hematological patients: An old or new question?

Annals of Hematology

Volumn 91, Issue 8, 2012, Pages 1299-1304

  Cattaneo, Chiara ^a   Antoniazzi, F ^a   Casari, S ^b   Ravizzola, G ^b   Gelmi, M ^b   Pagani, C ^a   D'Adda, M ^a   Morello, E ^a   Re, A ^a   Borlenghi, E ^a   Manca, N ^b   Rossi, G ^a  

^a Spedali Civili Piazza Spedali Civili ^*  (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Antibiotic resistance; Bloodstream infections; Hematological patients; Outcome; P.aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFTRIAXONE; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; DISEASE SURVEILLANCE; GRAM POSITIVE BACTERIUM; HEMATOLOGICAL PATIENT; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MORTALITY; MULTIDRUG RESISTANCE; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PATIENT; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CAUSE OF DEATH; COMMUNICABLE DISEASES; HEMATOLOGIC DISEASES; HEMATOLOGY; HUMANS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SURVIVAL ANALYSIS;

EID: 84864966021     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1424-3     Document Type: Article

References (31)

1. Gaytán-Martínez J, Mateos-García E, Sánchez-Cortés E et al (2000) Microbiological findings in febrile neutropenia. Arch Med Res 31:388-392
2. Cattaneo C, Quaresmini G, Casari S et al (2008) Recent changes in bacterial epidemiology and the emergence of fluoroquinoloneresistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 61:721-728 (Pubitemid 351321152)
3. Kern WV, Klose K, Jellen-Ritter AS et al (2005) Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 24:111-118 (Pubitemid 40487379)
4. Peleg AY, Hooper DC (2010) Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 362:1804-1813
5. Gudiol C, Calatayud L, Garcia-Vidal C et al (2010) Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors,molecular epidemiology and outcome. J Antimicrob Chemother 65:333-341
6. Irfan S, Idrees F, Mehraj V et al (2008) Emergence of Carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study. BMC Infect Dis 9:80
7. Paterson DL, Rogers BA (2010) How soon is now? The urgent need for randomized, controlled trials evaluating treatment of multidrugresistant bacterial infection. Clin Infect Dis 51:1245-1247
8. Bonomo RA, Szabo D (2006) Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 43(Suppl 2):S49-S56 (Pubitemid 44267140)
9. Giske CG, Monnet DL, Cars O et al (2008) Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 52:813-821 (Pubitemid 351358357)
10. Kang CI, Kim SH, Park WB et al (2005) Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 11:68-74 (Pubitemid 40365848)
11. Rangaraj G, Granwehr BP, Jiang Y et al (2010) Perils of quinolone exposure in cancer patients: breakthrough bacteremiawithmultidrugresistant organisms. Cancer 116:967-973
12. Micol JB, de Botton S, Guieze R et al (2006) An 18-case outbreak of drug-resistant Pseudomonas aeruginosa bacteriemia in hematology patients. Haematologica 91:1134-1138 (Pubitemid 44204785)
13. Caselli D, Cesaro S, Ziino O et al (2010) Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation.Haematologica 95:1612-1615
14. Trecarichi EM, Tumbarello M, Caira M et al (2011) Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica 96:e1-3
15. Cattaneo C, Casari S, Bracchi F et al (2010) Recent increase in enterococci, viridans streptococci, Pseudomonas spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution. Scand J Infect Dis 42:324-332
16. Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:427-431
17. Magiorakos AP, Srinivasan A, Carey RB et al (2011) Multidrugresistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. doi:10.1111/j.1469- 0691.2011.03570.x
18. Kang CI, Kim SH, Park WB et al (2005) Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 49:760-766
19. O'Grady NP, Alexander M, Dellinger EP et al (2002) Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 35:1281-1307 (Pubitemid 35448956)
20. Clinical and Laboratory Standard Institute (2007) Performance standards for antimicrobial susceptibility testing; seventeenth information supplement. CLSI document M100-S17, Wayne. PA.
21. Pagano L, Caira M, Candoni A et al (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91:1068-1075 (Pubitemid 44208634)
22. Pagano L, Caira M, Nosari A et al (2011) The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica 96:1366-1370
23. Chen CY, Tsay W, Tang JL et al (2010) Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect 138:1044-1051
24. Velasco E, Byington R, Martins CSA et al (2004) Bloodstream infection surveillance in a cancer centre: a prospective look at clinical microbiology aspects. Clin Microbiol Infect 10:542-549 (Pubitemid 38961580)
25. Viscoli C, Castagnola E (2002) Treatment of febrile neutropenia: what is new? Curr Opin Infect Dis 15:377-382 (Pubitemid 34816425)
26. Cheong HS, Kang CI, Wi YM et al (2008) Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia. Eur J Clin Microbiol Infect Dis 27:1219-1225
27. Paul M, Soares-Weiser K, Leibovici L (2003) Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 326:1111
28. Kumar A, Zarychanski R, Light B et al (2010) Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 38:1773-1785
29. Safdar N, Handelsman J, Maki DG (2004) Does combination antimicrobial therapy reducemortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 4:519-527 (Pubitemid 39077923)
30. Drgona L, Paul M, Bucaneve G, Calandra T et al (2007) The need for aminoglycosides in combination with b-lactams for high-risk, febrile neutropaenic patients with leukaemia. Eur J Cancer S5:13-22 (Pubitemid 47189741)
31. Tumbarello M, Repetto E, Trecarichi EM et al (2011) Multidrugresistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect 13:1-10